CAPR Capricor Therapeutics (CAPR) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001133869
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
103
13F, latest reported quarter
Conversions, 180 days
10
Codes C/M, not in net · $327.6K priced
What the filings say about CAPR
Insiders, 180 days
-$3.1M net sold
2 sellers · 0% of sales under a 10b5-1 plan
Capricor Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, CAPRICOR THERAPEUTICS, INC. insiders sold a net $3.1M of stock across 24 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 24, 2026.
- The trade is 78.9% of the 30,547 shares held after it.
- 1 other insider sold within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GENERAL COUNSEL Krasney Karen sold about $732.2K of CAPR on Jun 25, 2026; 1 other insider sold within 30 days and 103 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 24, 2026.
- The trade is 214.7% of the 11,223 shares held after it.
- 1 other insider sold within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Bergmann Anthony sold about $732.2K of CAPR on Jun 25, 2026; 1 other insider sold within 30 days and 103 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jun 22, 2026.
- The trade is 1.3% of the 30,547 shares held after it.
- 1 other insider sold within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GENERAL COUNSEL Krasney Karen sold about $12.0K of CAPR on Jun 24, 2026; 1 other insider sold within 30 days and 103 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jun 22, 2026.
- The trade is 3.6% of the 11,223 shares held after it.
- 1 other insider sold within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Bergmann Anthony sold about $12.0K of CAPR on Jun 24, 2026; 1 other insider sold within 30 days and 103 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on May 1, 2026.
- The trade is 1.6% of the 30,547 shares held after it.
- 1 other insider sold within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, GENERAL COUNSEL Krasney Karen sold about $15.0K of CAPR on Jun 22, 2026; 1 other insider sold within 30 days and 103 funds added in the latest 13F quarter.24 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$3.1M over 180 days
below 74% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
103 funds bought in last quarter
more than 70% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
43.6% of the float short (float per yahoo 2026-10-27) · 6.6 days to cover · settled 2026-10-15
the highest in Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 6 in the prior 90
Why it matters
The absence is the signal: 6 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch CAPR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-0.5%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CAPR: institutional holders (13F)
13F holdings, latest reported quarter
4,145,061 sh
$99.8M
4,099,900 sh
$98.7M
4,092,784 sh
$98.6M
3,397,150 sh
$81.8M
2,297,674 sh
$55.3M
Congress trades in CAPR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CAPR planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CAPR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Dorsey Wright SmallCap Momentum ETF
$2.6M position · as of 2026-05-31
0.6%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$52.5M position · as of 2026-06-30
0.5%
PROFUND VP BIOTECHNOLOGY
$231.9K position · as of 2026-06-30
0.5%
Select Pharmaceuticals Portfolio
$6.9M position · as of 2026-05-31
0.5%
Select Biotechnology Portfolio
$10.0M position · as of 2026-05-31
0.2%
VANGUARD U.S. MOMENTUM FACTOR ETF
$2.6M position · as of 2026-05-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.5M
$7.2M
$1.5M
+648%
n/a
2024
$1.5M
$5.1M
$899.9K
+258%
n/a
2023
$774.3K
$1.2M
$740.6K
+27%
n/a
2022
$1.3M
$2.2M
$796.1K
+32%
n/a
2021
$1.8M
$1.2M
$702.1K
-15%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $3.1M sold by insiders over 180 days, 103 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CAPR financials
Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$22.3M
four quarters, 2024-01-01 to 2024-12-31
Revenue, TTM CAPR
| FY Dec 2025 | $22.3M |
| FY Dec 2024 | $22.3M |
| FY Dec 2023 | $25.2M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | $244.9K |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | $11.1M |
| Sep 2024 | $2.3M |
At each fiscal year end
Single quarter
Net margin, TTM
-581.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CAPR
| FY Dec 2025 | -471.7% |
| FY Dec 2024 | -181.7% |
| FY Dec 2023 | -88.5% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -63.9% |
| Sep 2024 | -555.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$114.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CAPR
| FY Dec 2025 | -$72.7M |
| FY Dec 2024 | -$41.2M |
| FY Dec 2023 | -$26.9M |
| FY Dec 2022 | $2.9M |
| FY Dec 2021 | -$18.0M |
| Jun 2026 | -$35.5M |
| Mar 2026 | -$34.4M |
| Dec 2025 | -$25.2M |
| Sep 2025 | -$19.7M |
| Jun 2025 | -$20.4M |
| Mar 2025 | -$7.3M |
| Dec 2024 | -$15.3M |
| Sep 2024 | -$11.7M |
At each fiscal year end
Single quarter
Debt to equity
0.01x
long-term debt only, 2024-09-30 (21 months older than the period end); equity 2026-06-30
Debt to equity CAPR
| FY Dec 2025 | 0.01x |
| FY Dec 2024 | 0.02x |
| FY Dec 2023 | 0.15x |
| FY Dec 2022 | 0.29x |
| FY Dec 2021 | 0.11x |
| Jun 2026 | 0.01x |
| Mar 2026 | 0.01x |
| Dec 2025 | 0.01x |
| Sep 2025 | 0.04x |
| Jun 2025 | 0.03x |
| Mar 2025 | 0.03x |
| Dec 2024 | 0.02x |
| Sep 2024 | 0.05x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-30.80x
TTM operating cash flow over long-term debt only, 2024-09-30 (21 months older than the period end)
Cash flow to debt CAPR
| FY Dec 2025 | -20.68x |
| FY Dec 2024 | -11.85x |
| FY Dec 2023 | -7.58x |
| FY Dec 2022 | 1.46x |
| FY Dec 2021 | -4.98x |
| Jun 2026 | -30.80x |
| Mar 2026 | -27.44x |
| Dec 2025 | -20.68x |
| Sep 2025 | -18.08x |
| Jun 2025 | -15.70x |
| Mar 2025 | -13.38x |
| Dec 2024 | -11.85x |
| Sep 2024 | -10.90x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-73.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CAPR
| FY Dec 2025 | -46.6% |
| FY Dec 2024 | -48.2% |
| FY Dec 2023 | -129.6% |
| FY Dec 2022 | -134.5% |
| FY Dec 2021 | -67.2% |
| Jun 2026 | -73.7% |
| Mar 2026 | -56.4% |
| Dec 2025 | -46.6% |
| Sep 2025 | -107.8% |
| Jun 2025 | -120.2% |
| Mar 2025 | -75.4% |
| Dec 2024 | -48.2% |
| Sep 2024 | -102.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-51.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CAPR
| FY Dec 2025 | -39.9% |
| FY Dec 2024 | -35.3% |
| FY Dec 2023 | -41.0% |
| FY Dec 2022 | -63.5% |
| FY Dec 2021 | -52.7% |
| Jun 2026 | -51.5% |
| Mar 2026 | -47.7% |
| Dec 2025 | -39.9% |
| Sep 2025 | -74.7% |
| Jun 2025 | -81.4% |
| Mar 2025 | -54.2% |
| Dec 2024 | -35.3% |
| Sep 2024 | -52.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital CAPR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-61.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CAPR
| FY Dec 2025 | -46.1% |
| FY Dec 2024 | -48.1% |
| FY Dec 2023 | -89.2% |
| FY Dec 2022 | -93.2% |
| FY Dec 2021 | -60.8% |
| Jun 2026 | -61.3% |
| Mar 2026 | -56.6% |
| Dec 2025 | -46.1% |
| Sep 2025 | -101.5% |
| Jun 2025 | -121.2% |
| Mar 2025 | -74.2% |
| Dec 2024 | -48.1% |
| Sep 2024 | -94.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CAPR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$337.1M
market value at close 2026-10-27 on 2026-08-13 shares, plus long-term debt only, 2024-09-30 (21 months older than the period end), minus cash 2026-06-30
Enterprise value CAPR
| FY Dec 2025 | $1.0B |
| FY Dec 2024 | $619.6M |
| FY Dec 2023 | $139.3M |
| FY Dec 2022 | $91.2M |
| FY Dec 2021 | $39.2M |
| Jun 2026 | $1.4B |
| Mar 2026 | $1.6B |
| Dec 2025 | $1.0B |
| Sep 2025 | $313.5M |
| Jun 2025 | $434.0M |
| Mar 2025 | $408.0M |
| Dec 2024 | $619.6M |
| Sep 2024 | $429.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-32.4%
TTM free cash flow over market value at close 2026-10-27
FCF yield CAPR
| FY Dec 2025 | -5.5% |
| FY Dec 2024 | -6.6% |
| FY Dec 2023 | -17.9% |
| FY Dec 2022 | +3.0% |
| FY Dec 2021 | -25.4% |
| Jun 2026 | -8.2% |
| Mar 2026 | -5.7% |
| Dec 2025 | -5.5% |
| Sep 2025 | -19.0% |
| Jun 2025 | -12.0% |
| Mar 2025 | -10.8% |
| Dec 2024 | -6.6% |
| Sep 2024 | -7.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CAPR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $0 | $22.3M | $25.2M | $2.6M |
| Operating income | -$108.1M | -$42.6M | -$24.1M | -$29.7M |
| Net income | -$105.0M | -$40.5M | -$22.3M | -$29.0M |
| EPS (diluted) | -2.26 | -1.15 | -0.83 | -1.18 |
| Operating cash flow | -$69.8M | -$40.0M | -$25.6M | $4.9M |
| Cash | $287.8M | $11.3M | $14.7M | $9.6M |
| Long-term debt | n/a | n/a | $3.4M | $3.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
CAPR Stock Sonar score 6/7 axes
Find similar shapesCompareCAPR ranks highest on institutional and government (70th percentile) and financial health (45th), and lowest on growth (1st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CAPR filings, in plain words
Are Capricor Therapeutics insiders buying or selling CAPR?
In the 180 days to 2026-10-28, Capricor Therapeutics insiders were net sellers, a net $3.1M across purchases and sales reported on Form 4, by 2 sellers.
Read the full summary
In the 180 days to 2026-10-28, Capricor Therapeutics insiders were net sellers of CAPR, a net $3.1M across purchases and sales reported on Form 4 by 2 sellers. None of the 8 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
